Gray, KJ; Kafulafula, G; Matemba, M; Kamdolozi, M; Membe, G; French, N (2011) Group B Streptococcus and HIV Infection in Pregnant Women, Malawi, 2008-2010. Emerging infectious diseases, 17 (10). pp. 1932-1935. ISSN 1080-6040 DOI: https://doi.org/10.3201/eid1710.102008

Downloaded from: http://researchonline.lshtm.ac.uk/19142/

DOI: 10.3201/eid1710.102008

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Group B Streptococcus and HIV Infection in Pregnant Women, Malawi, 2008–2010

Katherine J. Gray, George Kafulafula,1 Mary Matemba, Mercy Kamdolozi, Gladys Membe, and Neil French

To determine whether an association exists between group B streptococcus carriage and HIV infection, we recruited 1,857 pregnant women (21.7% HIV positive) from Queen Elizabeth Central Hospital, Blantyre, Malawi. Overall, group B streptococcus carriage was 21.2% and did not differ by HIV status. However, carriage was increased among HIV-positive women with higher CD4 counts.

Group B streptococcus (GBS) is the major cause of neonatal meningitis and septicemia in Malawi, a problem that has only recently been recognized (1). A similar pattern of disease has emerged from other countries in eastern and southern Africa (2–8). The geographic distribution of these reports led us to speculate that an association exists between GBS and HIV infection. Carriage of GBS is a prerequisite for the development of early-onset neonatal GBS disease (9) and is a convenient endpoint for a cross-sectional study to assess the interaction of GBS and HIV.

The Study

Pregnant women (≥16 years of age) in their third trimester of pregnancy were recruited from the labor ward of Queen Elizabeth Central Hospital, Blantyre (QECH), during October 2008–March 2010. Recruitment was performed by a single study midwife on Sunday–Thursday each week from 7:30 AM to 4:00 PM, when the midwife was not required to provide emergency care. Women were excluded if they were deemed to be too sick by the study midwife. Following the patient’s signed informed consent, medical and reproductive history was recorded, low vaginal and rectal swab specimens were obtained, and after appropriate counseling, a blood sample was obtained to either confirm or determine HIV status. CD4 counts were determined for those who were HIV positive. In accordance with Ministry of Health Guidelines, prevention of mother-to-child transmission care (PMTCT) was offered to women who were HIV infected (10); PMTCT was adapted as appropriate to the woman’s CD4 count. The mothers were not followed after they left the hospital.

Swab specimens were placed into Todd-Hewitt broth (Oxoid Ltd, Basingstoke, UK) supplemented with 15 μg/mL nalidixic acid and 10 μg/mL colistin and then incubated for 18–24 h. GBS were identified by phenotypic characteristics, CAMP test, and serologic analysis (Oxoid). Serotyping of GBS was performed by use of a commercial serotyping kit (Statens Serum Institut, Copenhagen, Denmark). HIV testing was conducted by using a method based on rapid tests (11).

The study aimed to recruit 1,950 women to show a GBS carriage prevalence increased by ≥40% in the HIV-positive women at a significance level of 5% and power of 80%. This assumed 20% HIV prevalence in the labor ward attendees (thus a 4:1 ratio of HIV-negative to HIV-positive women) and 15% GBS carriage in HIV-negative women. Two analyses were planned a priori. The primary analysis was to compare GBS carriage prevalence by HIV status; the secondary analysis was the association of GBS carriage by CD4 count in HIV-infected women. The study was approved by the College of Medicine Research and Ethics Committee of the University of Malawi and the Ethics Committee of the London School of Hygiene and Tropical Medicine.

A total of 16,456 women attended QECH labor ward during the study period. Of these women, 11,861 attended on a recruitment day, and 8,099 attended during recruitment hours, of whom 1,857 (23%) were recruited into the study (Table 1). The 2 primary reasons for not enrolling women were that they were in the second stage of labor and that their hospitalization was caused by an emergency or due to a complicated pregnancy (50.8% of all attendees). The remaining nonrecruits were women who could not be assessed by the study midwife within the specified time. During the same period, 14,783 total deliveries took place at QECH, with 380 multiple births (2.6%), 2,962 caesarean sections (20.0%), 514 stillbirths (3.5%), 29 neonatal deaths, and 20 maternal deaths recorded on the labor ward. The percentage of women in the study who had multiple births (2.7%) and caesarean sections (20.6%) was the same as that in the larger group attending the labor ward. However, the percentage with stillbirths (1.6%) was less, which is consistent with the exclusion of women who were attending the ward for complicated pregnancies or emergency medical conditions.

Author affiliations: College of Medicine, Blantyre, Malawi (K.J. Gray, G. Kafulafula, M. Kamdolozi, G. Membe); Karonga Prevention Study, Karonga, Malawi (M. Matemba, N. French); and London School of Hygiene and Tropical Medicine, London, UK (N. French)

DOI: http://dx.doi.org/10.3201/eid1710.102008

1Deceased.
Of the study participants with HIV, >80% had been tested before attending QECH labor ward, most as a part of the PMTCT process. Only 125 (31%) of those with positive test results had received any formal HIV clinic care. GBS carriage was detected in 21.7% of the HIV-negative women and 19.4% of the HIV-positive women ($\chi^2 = 0.99, p = 0.32$) (Table 2). In the HIV-positive women, a difference in GBS carriage was noted by CD4 level: women with CD4 counts >500 cells/mm$^3$ were >2× more likely than those with counts <200 cells/mm$^3$ to be GBS carriers. When adjusted for antiretroviral treatment, the number of children previously borne, and age, this finding persisted (Table 2). Carriage in the HIV-infected group with CD4 counts >500 cells/mm$^3$ (28.2%) was higher than in the HIV-uninfected women (21.7%), but the difference did not reach significance in an unadjusted comparison ($\chi^2 = 2.65, df = 1, p = 0.11$).

To test for unrecorded cotrimoxazole use as an explanation of the CD4-associated carriage findings (i.e., that sicker women with more advanced disease might be
more likely to take cotrimoxazole), we performed a post-hoc subgroup analysis on women who had reported no previous HIV testing or care before their recent PMTCT test, considering it unlikely that they would be taking cotrimoxazole. In this group of 277 women (13 with missing CD4 counts), the trend for increasing odds of carriage with higher CD4 count persisted. The prevalence of carriage in the CD4 groups of <200, 200–500, and >500 cells/mm$^3$ was 15.9%, 19.1% (odds ratio [OR] 1.25, 200–500 cells/mm$^3$ vs. <200 cells/mm$^3$), and 31.0% (OR 2.37, >500 cells/mm$^3$ vs. <200 cells/mm$^3$), respectively (p = 0.03, by $\chi^2$ test for linear trend). This pattern was similar in the 125 participants who reported accessing HIV care, with ORs of 1.6 and 2.8 in the same CD4 group comparisons.

**Conclusions**

In the primary analysis comparing carriage prevalence by HIV status, no overall difference in GBS carriage by HIV status was detected. The overall carriage frequency of GBS of $\approx$20% is comparable with those in other reports from Africa and the industrialized world. However, in the subgroup analysis of HIV-positive women, contrary to our expectations, GBS carriage was significantly increased at higher CD4 counts. Unrecorded use of antimicrobial drugs, particularly cotrimoxazole prophylaxis, as a confounder for this association was considered and dismissed as an explanation for these findings.

Antiretroviral treatment was not shown as an independent risk factor for carriage, but the cross-sectional design of this study precludes any firm conclusions. With increasing numbers of HIV-positive women using antiretroviral drugs, the effect of treatment-induced improvements in CD4 count and the potential for increased GBS carriage merit further investigation.

Our results showed a trend toward higher GBS carriage in HIV-infected women with CD4 counts >500 cells/mm$^3$.

**Table 2. Associations with GBS carriage among 340 pregnant women with and without HIV infection, Malawi, 2008–2010**

| Variable | GBS carriage, no. positive for variable/no. total (%) | OR (95% CI) | Adjusted OR (95% CI) |
|-----------------|------------------------------------------|--------------|----------------------|
| All study participants | 390/1,857 (21.0) | – | – |
| HIV-negative participants | 313/1,441 (21.7) | Reference | Reference |
| HIV-positive participants | 77/397 (19.4) | 0.88 (0.66–1.17) | 0.84 (0.63–1.12) |
| Age group, y† | | | |
| 16–19 | 68/345 (19.7) | 2.29 (0.68–7.76) | 1.41 (0.40–4.92) |
| 20–24 | 122/582 (21.0) | 2.48 (0.74–8.28) | 1.96 (0.58–6.63) |
| 25–29 | 113/498 (22.7) | 2.74 (0.82–9.18) | 2.43 (0.72–8.18) |
| 30–34 | 60/261 (23.0) | 2.79 (0.82–9.48) | 2.59 (0.76–8.88) |
| 35–39 | 24/122 (19.7) | 2.29 (0.64–8.15) | 2.03 (0.56–7.33) |
| ≥40 | 3/31 (9.7) | Reference | Reference |
| First pregnancy | 137 (24.0) | 1.30 (1.01–1.65) | 1.62 (1.19–2.19) |
| Second or subsequent pregnancy | 244 (19.6) | Reference | Reference |
| Recruited during rainy season | 235 (22.4) | 1.18 (0.94–1.50) | – |
| Recruited during nonrainy season | 155 (19.6) | Reference | – |
| Birth weight ≤2.5 kg | | | |
| No | 307 (21.5) | Reference | – |
| Yes | 71 (19.4) | 0.88 (0.65–1.17) | – |
| Multiple birth | | | |
| No | 381 (21.3) | Reference | – |
| Yes | 9 (18.0) | 0.81 (0.34–1.71) | – |

HIV-positive subgroup‡:

Antiretroviral treatment

| Variable | GBS carriage, no. positive for variable/no. total (%) | OR (95% CI) | Adjusted OR (95% CI) |
|-----------------|------------------------------------------|--------------|----------------------|
| No | 67 (20.4) | Reference | Reference |
| Yes | 15 (18.1) | 0.91 (0.45–1.75) | 1.14 (0.58–2.26)§ |
| CD4 cell count/mm$^3$¶ | | | |
| <200 | 9 (14.1) | Reference | Reference |
| 200–499 | 34 (17.2) | 1.27 (0.57–2.81) | 1.30 (0.58–2.92)§ |
| >500 | 33 (28.2) | 2.40 (1.07–5.41) | 2.55 (1.10–5.90) |

*GBS, group B streptococcus; OR, odds ratio; CI, confidence interval; –, not applicable. Adjusted OR derived from logistic regression by use of backward stepwise approach. Final model retained variables with p value <0.1 along with age group and parity because of their known association with GBS carriage.

†$\chi^2$ test for linear trend, p = 0.93.

‡$\chi^2$ test for linear trend, p = 0.01.

§Adjusted model includes age group, first pregnancy vs. second or subsequent pregnancies; antiretroviral treatment, and CD4 count for the HIV-positive subgroup.

¶19 participants had no CD4 count available.
than in the HIV-uninfected women. This association may be consistent with a GBS-specific immune defect, which would concur with what we understand about HIV immunopathology and related capsulate bacteria (12). We propose that this higher carriage is obscured by competitive exclusion of GBS in the vagina of women with advanced HIV as a consequence of ecologic changes in the microbial flora (13). Increased presence of bacterial vaginosis and anaerobes at low CD4 counts is a feature of HIV, and these conditions may alter the ability of GBS to colonize the vagina (14,15). Specific studies to investigate anti-GBS immunity and the interactions of the microbial flora in HIV-infected women are required.

Neonatal GBS disease is common in Africa, and disease risk is intimately connected to GBS carriage. The public health consequences of these carriage findings are unclear at present, but further investigation of the interaction of HIV and GBS carriage and risk of neonatal disease is merited, given the recent rise in frequency of GBS infection.

Acknowledgments
We thank the staff and patients of the obstetric unit at QECH for their support.

We dedicate this article to Dr George Kafufula, who died suddenly before completion of the study.

The work was funded by the Meningitis Research Foundation (grant number 0801.0) with support from the Wellcome Trust-funded Karonga Prevention Study (079827). N.F. has received an honorarium from Novartis pharmaceuticals for talking on their behalf. M.J. and N.K.J. acknowledge support from the Wellcome Trust-funded Karonga Prevention Study (079827). N.F. has received (grant number 0801.0) with support from the Wellcome Trust–African Alliance for Health and Population Research (grant number 0802.0) for their support.

References
1. Milledge J, Calis JC, Graham SM, Phiri A, Wilson LK, Soko D, et al. Aetiology of neonatal sepsis in Blantyre, Malawi: 1996–2001. Ann Trop Paediatr. 2005;25:101–10. doi:10.1179/146532805X45692
2. Madhi SA, Radebe K, Crewe-Brown H, Frasch C, Arakere G, Mokhachane M, et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr. 2003;23:15–23. doi:10.1179/0003498032002814
3. Nathoo KJ, Mason PR, Chimbiro TH. Neonatal septicaemia in Harare Hospital: aetiology and risk factors. The Puerperal Sepsis Study Group. Cent Afr J Med. 1990;36:150–6.
4. Signaääge B, Roca A, Mandomando I, Morais L, Quintó L, Sacarlal J, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J. 2009;28:108–13. doi:10.1097/INF.0b013e318187a87d
5. Berkley JA, Lowe BS, Mwangi T, Williams T, Bauni E, Mwarumba S, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med. 2005;352:39–47. doi:10.1056/NEJMoa040275
6. Laving AM, Musoke RN, Musunza AO, Revathi G. Neonatal bacterial meningitis at the newborn unit of Kenyatta National Hospital. East Afr Med J. 2003;80:565–62.
7. Matee MI, Mbre R. Pathogenic isolates in meningitis patients in Dar Es Salaam, Tanzania. East Afr Med J. 2001;78:458–60.
8. Talbert AW, Mwaniki M, Mwarumba S, Newton CR, Berkley JA. Invasive bacterial infections in neonates and young infants born outside hospital admitted to a rural hospital in Kenya. Pediatr Infect Dis J. 2010;29:945–9.
9. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia: Saunders; 2001. p. 1091–156.
10. Malawi Ministry of Health. Prevention of mother to child transmission of HIV and paediatric HIV care guidelines. 2nd ed. National treatment guideline, Malawi. Lilongwe (Malawi): Government of Malawi; 2008 [cited 2011 Jul 21]. http://www.aidsiar-one.com/treatment_aids_guidelines_use_antiretroviral_therapy_malawi
11. Molesworth AM, Ndhlouvu R, Banda E, Saul J, Ngwira, B, Glynn J, et al. High accuracy of home-based community rapid HIV testing in rural Malawi. J Acquir Immune Defic Syndr. 2010;55:625–30. doi:10.1097/QAI.0b013e3181918628
12. French N, Moore M, Haikala R, Käilyhty H, Gilks CF. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis. 2004;190:707–12. doi:10.1086/421911
13. Spear GT, Sikaroodi M, Zariffard MR, Landay AL, French AL, Gillevet PM. Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis. 2008;198:1131–40. doi:10.1086/591942
14. Jamieson DJ, Duerr A, Klein RS, Paramsothy P, Brown W, Cunynghime JS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol. 2001;98:656–63. doi:10.1016/S0029-7844(01)01525-3
15. Kubota T, Nojima S, Itoh S. Vaginal bacterial flora of pregnant women colonized with group B streptococcus. J Infect Chemother. 2002;8:326–30. doi:10.1007/s10156-002-0190-x

Address for correspondence: Katherine J. Gray, Department of Microbiology, College of Medicine, Private Bag 360, Blantyre, Malawi; email: kgray@medcol.mw

Now in PubMed Central
Emerging Infectious Diseases current and past content now in the National Library of Medicine’s digital archive.